Pipeline

A growing
portfolio of skin treatments.

Our unique dermatology drug development platform and expertise fuel our commitment to meaningful innovation that meets the urgent needs of patients.

Our growing portfolio and robust pipeline.

Topical Preclinical Phase 1 Phase 2 Phase 3 NDA Submitted to FDA FDA Approved
Topical Roflumilast Cream

PDE4i*
Topical Roflumilast Cream

PDE4i*
Plaque Psoriasis 0.3%
         
Topical Roflumilast Cream

PDE4i*
Topical Roflumilast Cream

PDE4i*
Atopic Dermatitis 0.15%
         
AD 0.05% (2‑5 yr)
         
AD 0.05% (3‑24 mo)
         
Topical Roflumilast Foam

PDE4i*
Topical Roflumilast Foam

PDE4i*
Seborrheic Dermatitis 0.3%
         
Scalp and Body Psoriasis 0.3%
         
ARQ-255

JAK1i†
ARQ-255

JAK1i†
Alopecia Areata
         
ARQ-252

JAK1i†
ARQ-252

JAK1i†
Chronic Hand Eczema
         
Vitiligo
         

Biologic
ARQ-234

CD200R agonist‡
ARQ-234

CD200R agonist‡
Atopic Dermatitis
         

*Phosphodiesterase-4 inhibitor

†Janus kinase 1 inhibitor

‡CD200 receptor agonist

Arcutis’ pipeline will change as molecules move through the drug development process. The safety and efficacy of the investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.

There is no guarantee that these therapies or uses will be commercialized. Some of the content on this page is not intended for users outside the US.

Tackling the most persistent challenges in treating immune-mediated dermatological diseases and conditions.

Arcutis focuses on biologically validated targets that offer the opportunity for development and commercialization on a shorter timeline to regulatory approval, at a lower overall cost of development. 

Patient with seborrheic dermatitis on face

Our robust pipeline includes multiple clinical programs evaluating PDE4, JAK1 and CD200R agonists, for a range of inflammatory dermatological conditions.

Featuring multiple clinical programs for a range of immune-mediated conditions, our pipeline includes formulations that have achieved significant results in our clinical trials.

Combined with our unique formulation expertise, we have developed proprietary topical formulations optimized to deliver medication into the skin.

Learn more about how our pipeline is bringing meaningful innovation to life.

Contact Us

Meaningful innovation
is here.

See what our fifth FDA approval means for the treatment of immune-mediated skin conditions.

Learn More
You are leaving Arcutis.com.

This link will send you to a site maintained by an independent third party.
Arcutis is not responsible for the content on that site.

Cancel Continue